Benzenesulfonamide as a novel, pharmaceutical small molecule inhibitor on Al3 gene expression and oxidative stress in Alzheimer's Wistar rats

Alzheimer's disease (AD) is the most prevalent acute neurodegenerative disease described by memory loss and other cognitive functions. Benzenesulfonamide, a novel, potent, and small organic molecule, was synthesized to investigate its effects on the levels of oxidative biomarkers (GPx, ROS, and MDA) and expression of beta-amyloid peptides (Al340 and Al342) in the pathology of AD. The results were compared with the rivastigmine drug. Applying benzenesulfonamide to Alzheimer's-induced Wistar rats showed a significant increase in the level of oxidative biomarkers (GPx, ROS, and MDA) in both the brain and blood serum as well as amyloid-l340 and 42 gene expressions. Therefore, benzenesulfonamide could be considered a novel therapeutic agent against AD. & COPY; 2023 Elsevier Inc. All rights reserved.

Automated summary

Alzheimer's disease is a common neurodegenerative disease characterized by memory loss and cognitive impairment. A newly synthesized molecule called benzenesulfonamide has been found to affect oxidative biomarkers and the expression of beta-amyloid peptides in the pathology of AD. When administered to rats with Alzheimer's, benzenesulfonamide significantly increased the levels of oxidative biomarkers and amyloid gene expressions. Therefore, it could be a potential therapeutic agent for Alzheimer's disease.